ProQR Therapeutics (PRQR) Equity Average (2022 - 2025)

ProQR Therapeutics (PRQR) has disclosed Equity Average for 4 consecutive years, with $76.1 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 9.3% to $76.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.1 million through Dec 2025, up 9.3% year-over-year, with the annual reading at $76.1 million for FY2025, 9.11% up from the prior year.
  • Equity Average hit $76.1 million in Q4 2025 for ProQR Therapeutics, up from $69.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $99.3 million in Q4 2022 to a low of $56.3 million in Q4 2023.
  • Historically, Equity Average has averaged $75.3 million across 4 years, with a median of $72.8 million in 2024.
  • Biggest five-year swings in Equity Average: crashed 43.31% in 2023 and later increased 23.63% in 2024.
  • Year by year, Equity Average stood at $99.3 million in 2022, then plummeted by 43.31% to $56.3 million in 2023, then rose by 23.63% to $69.6 million in 2024, then grew by 9.3% to $76.1 million in 2025.
  • Business Quant data shows Equity Average for PRQR at $76.1 million in Q4 2025, $69.6 million in Q4 2024, and $56.3 million in Q4 2023.